GenSight Financial Statements From 2010 to 2025
| GSGTF Stock | USD 0.19 0.00 0.00% |
Check GenSight Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GenSight Biologics' main balance sheet or income statement drivers, such as , as well as many indicators such as . GenSight financial statements analysis is a perfect complement when working with GenSight Biologics Valuation or Volatility modules.
GenSight |
GenSight Biologics SA Company Operating Margin Analysis
GenSight Biologics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current GenSight Biologics Operating Margin | (6.59) % |
Most of GenSight Biologics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GenSight Biologics SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, GenSight Biologics SA has an Operating Margin of -6.5859%. This is 81.23% lower than that of the Healthcare sector and 94.12% lower than that of the Biotechnology industry. The operating margin for all United States stocks is 19.53% higher than that of the company.
GenSight Biologics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining GenSight Biologics's current stock value. Our valuation model uses many indicators to compare GenSight Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GenSight Biologics competition to find correlations between indicators driving GenSight Biologics's intrinsic value. More Info.GenSight Biologics SA is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the GenSight Biologics' earnings, one of the primary drivers of an investment's value.About GenSight Biologics Financial Statements
GenSight Biologics stakeholders use historical fundamental indicators, such as GenSight Biologics' revenue or net income, to determine how well the company is positioned to perform in the future. Although GenSight Biologics investors may analyze each financial statement separately, they are all interrelated. For example, changes in GenSight Biologics' assets and liabilities are reflected in the revenues and expenses on GenSight Biologics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in GenSight Biologics SA. Please read more on our technical analysis and fundamental analysis pages.
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France. Gensight Biologics is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| PRNEX | T Rowe Price | |
| RPBAX | T Rowe Price | |
| PRDGX | T Rowe Price | |
| PRFDX | T Rowe Price | |
| RPBAX | T Rowe Price |
Other Information on Investing in GenSight Pink Sheet
GenSight Biologics financial ratios help investors to determine whether GenSight Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GenSight with respect to the benefits of owning GenSight Biologics security.